Yang et al. developed polyclonal neutralizing anti-CHI3L1 antibodies (nCHI3L1 Abs) and assessed their efficacy in lung, pancreas, and colon cancer allograft models [143]. Here, CHI3L1 is linked to malignant colon neoplasm.